P

Inventor

STAELENS STEPHANIE

BE23 patents
⚠️ This page may combine multiple inventors who share the name “STAELENS STEPHANIE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ABLYNX NV

14 patents
US10858418B2Dec 8, 2020

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

ABLYNX NV18 citations93
US9803001B2Oct 31, 2017

Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections

ABLYNX NV4 citations84
US11192937B2Dec 7, 2021

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

ABLYNX NV5 citations83
US11192938B2Dec 7, 2021

Serum albumin binding proteins containing immunoglobulin single variable domains

ABLYNX NV5 citations83
US11414481B2Aug 16, 2022

Serum albumin binders

ABLYNX NV6 citations82
US11414480B2Aug 16, 2022

Serum albumin binding immunoglobulin single variable domains

ABLYNX NV6 citations78
US12516105B2Jan 6, 2026

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

ABLYNX NV1 citations74
US12006352B2Jun 11, 2024

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

ABLYNX NV1 citations72
US11644471B2May 9, 2023

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

ABLYNX NV2 citations72
US9834611B2Dec 5, 2017

Single variable domain antibodies against OX40L, constructs and therapeutic use

ABLYNX NV2 citations70
US11028151B2Jun 8, 2021

Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections

ABLYNX NV0 citations62
US11466089B2Oct 11, 2022

Chemokine receptor binding polypeptides

ABLYNX NV0 citations61
US11897944B2Feb 13, 2024

Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin

ABLYNX NV1 citations59
US10822425B2Nov 3, 2020

Single variable domain antibodies against OX40L, constructs and therapeutic use

ABLYNX NV0 citations49

BOEHRINGER INGELHEIM INT

4 patents

NOVARTIS AG

2 patents

VERDONCK FRANK

1 patent

DEPLA ERIK

1 patent

REVETS HILDE ADI PIERRETTE

1 patent